ストックスクリーナーアプリを入手
0.8761
3.19%
-0.0289
前日終値:
$0.905
開ける：
$0.8999
24時間の取引高:
117.83K
Relative Volume:
0.69
時価総額：
$52.92M
収益：
-
当期純損益:
$-112.67M
株価収益率:
-0.4493
EPS:
-1.95
ネットキャッシュフロー:
$-79.26M
1週間 パフォーマンス:
+0.93%
1か月 パフォーマンス:
+0.63%
6か月 パフォーマンス:
-2.67%
1年 パフォーマンス:
-8.74%
1日の値動き範囲:
$0.86
$0.915
1週間の範囲:
$0.85
$0.935
52週間の値動き範囲:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
KRON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.8761 | 52.92M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-11-14 | ダウングレード | TD Cowen | Buy → Hold |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-06-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-03 | 開始されました | Cowen | Outperform |
| 2020-11-03 | 開始されました | Goldman | Buy |
| 2020-11-03 | 開始されました | Jefferies | Buy |
| 2020-11-03 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Kronos Bio Inc (KRON) 最新ニュース
Kronos Bio ends lease early, pays $1.4 million settlement - Investing.com Australia
Kronos Bio ends lease early, pays $1.4 million settlement By Investing.com - Investing.com Canada
Kronos Bio Announces Lease Termination Agreement - TipRanks
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors - The Manila Times
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023) - Yahoo Finance
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Kronos Bio earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
Kronos Bio, Inc. SEC 10-K Report - TradingView
China Revives Its Carbon Credit Market: Price Swings & Future Outlook - The Globe and Mail
Navigating the U.S. Planting Season with Enhanced Risk Management - The Globe and Mail
Shootin' the Bull about cattle feeders - The Globe and Mail
KRONOS BIO Earnings Preview: Recent $KRON Insider Trading, Hedge Fund Activity, and More - Nasdaq
Kronos Bio (KRON) to Release Quarterly Earnings on Thursday - Defense World
Kronos Bio Insider Ups Holding By 36% During Year - Yahoo Finance
Kronos Bio, Inc. (NASDAQ:KRON) Shares Sold by Partners Capital Investment Group LLP - MarketBeat
Peapod Lane Capital LLC Purchases New Position in Kronos Bio, Inc. (NASDAQ:KRON) - MarketBeat
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5% - MarketBeat
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully - Yahoo Finance
Analyzing Kronos Bio (NASDAQ:KRON) and Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8% – Here’s What Happened - Defense World
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8%Should You Sell? - MarketBeat
Kronos Bio ends partnership with Genentech By Investing.com - Investing.com Australia
Kronos Bio ends partnership with Genentech - Investing.com India
Kronos Bio Ends Collaboration with Genentech and Roche - TipRanks
Kronos Bio Inc (KRON) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):